The landscape of bispecific T cell engager in cancer treatment
Abstract T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies for redirecting T cells to treat can...
Saved in:
Main Authors: | Shujie Zhou (Author), Mingguo Liu (Author), Fei Ren (Author), Xiangjiao Meng (Author), Jinming Yu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
by: Tian Huan, et al.
Published: (2023) -
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021) -
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
by: Richard Burt, et al.
Published: (2019) -
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
by: Peter N. Morcos, et al.
Published: (2021) -
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
by: Han Ping Loh, et al.
Published: (2023)